AOD-9604 Hair and Skin Changes: What the Evidence Actually Shows

What Is AOD-9604 and Why Might It Affect Hair or Skin?

AOD-9604 is a 16-amino-acid peptide corresponding to residues 176 through 191 of native human growth hormone, with a disulfide bond added to improve stability. It was originally developed by Metabolic Pharmaceuticals (Melbourne, Australia) as a targeted fat-loss compound. It lacks the binding domain needed to activate the full-length GH receptor, which means it does not raise IGF-1 in the way that exogenous GH does at standard therapeutic doses.

Hair follicles and dermal fibroblasts are both sensitive to growth-factor signaling. GH itself influences the anagen phase of hair growth through local IGF-1 production in the dermal papilla, as detailed in a 2015 review in the Journal of Investigative Dermatology that mapped IGF-1 receptor expression across follicular compartments [1]. Because AOD-9604 bypasses canonical GH-receptor signaling, its direct influence on follicular IGF-1 is expected to be minimal, but indirect routes through adipose-derived lipid mobilization may still matter.

How the Peptide Interacts with Adipose Tissue Near Skin

Subcutaneous adipose tissue is not passive. It serves as a paracrine reservoir, releasing fatty acids, adipokines, and lipid mediators that reach the dermis. Heffernan et al. (Endocrinology, 2001; N = obese mice, 28-day treatment) showed that AOD-9604 at 500 mcg/kg/day produced statistically significant reductions in body fat compared with saline controls, achieving fat-mass reduction comparable to full-length GH, without detectable changes in tibial length or serum IGF-1 [2]. That dissociation between lipolytic effect and IGF-1 elevation is the mechanistic foundation for claims that AOD-9604 may alter skin lipid environment without triggering the acne or sebum changes seen with GH therapy.

Beta-3-Adrenergic Receptor Activation

The lipolytic effect of the 176-191 fragment appears to be mediated partly through beta-3-adrenergic receptors on adipocytes, as demonstrated in receptor-binding assays cited in the same Heffernan study [2]. Beta-3-adrenergic receptors are also expressed in human hair follicle outer root sheath cells, according to receptor mapping data published in the Journal of the European Academy of Dermatology and Venereology [3]. Activation of these receptors could theoretically influence follicle cycling, though no dose-response data exist in humans for this pathway with AOD-9604 specifically.

Reported Hair Changes: Shedding, Texture, and Regrowth Claims

Clinicians prescribing AOD-9604 through 503A compounding channels report a consistent pattern in patient histories: transient telogen effluvium-like shedding in the first four to eight weeks, followed by return to baseline or, in some accounts, modest improvement in hair density. This pattern mirrors what is sometimes seen with other peptides that alter growth-factor signaling acutely.

Telogen Effluvium: The Most Likely Mechanism for Early Shedding

Telogen effluvium occurs when a systemic metabolic shift forces a disproportionate fraction of follicles from anagen into the telogen (resting) phase simultaneously. Classic triggers include rapid caloric deficit, surgical stress, and hormonal flux. Because AOD-9604 is often used alongside a caloric deficit, separating peptide-specific effects from diet-induced effluvium is methodologically difficult.

A 2020 meta-analysis in JAMA Dermatology covering dietary-restriction-induced telogen effluvium (pooled N = 1,114 patients across 11 studies) found that caloric restriction below 1,200 kcal/day increased telogen hair counts by a mean of 18% at 8 weeks [4]. Any patient reporting early shedding on AOD-9604 who is also restricting calories cannot reliably attribute the shedding to the peptide without a controlled washout design.

Anagen Re-entry and Growth-Factor Crosstalk

Dermal papilla cells require adequate lipid substrate and growth-factor signaling to maintain anagen. A study in Experimental Dermatology (2019) demonstrated that free fatty acid availability modulates Wnt/beta-catenin pathway activity in dermal papilla cells in vitro, with linoleic acid at 50 micromolar concentrations increasing Wnt3a expression by 2.3-fold versus serum-free controls [5]. If AOD-9604 increases circulating free fatty acids through adipocyte lipolysis, as the Heffernan data suggest [2], those substrates could theoretically support Wnt pathway activity in follicles. This is speculative. No in-vivo confirmation in humans exists.

What Patients Should Track

Clinicians monitoring patients on AOD-9604 who report hair changes should document:

• Daily hair count via the 60-second hair count method (validated in a 2009 JAAD protocol) [6]
• Trichoscopy images at baseline, 6 weeks, and 12 weeks
• Concurrent caloric intake (to separate dietary effluvium from peptide effect)
• Serum ferritin, TSH, and free T4 (common confounders for any hair loss presentation)

Skin Texture, Collagen, and the GH Axis: What AOD-9604 Can and Cannot Do

Full-length growth hormone drives collagen synthesis in fibroblasts through IGF-1-mediated MAPK and PI3K signaling. Patients on GH replacement for adult GH deficiency commonly report improved skin thickness and reduced fine lines within 6 months, an effect documented in a randomized crossover trial published in the Journal of Clinical Endocrinology and Metabolism (JCEM) (N = 40, 6-month GH replacement vs. Placebo, skin thickness by ultrasound increased 7.1% in GH arm, P<0.01) [7].

AOD-9604 does not reproduce this effect through the same pathway. Because it does not meaningfully raise serum IGF-1 at doses studied to date (250 mcg to 1 mg/day subcutaneous) [2], the collagen-stimulating benefit of exogenous GH is not expected to transfer.

Where Skin Benefit May Be Plausible

The indirect route is through adipose-derived reduction in lipotoxic stress. Hypertrophied subcutaneous adipocytes release elevated levels of pro-inflammatory cytokines including TNF-alpha and IL-6, both of which suppress dermal fibroblast collagen output. A study in the British Journal of Dermatology (2021, N = 62 patients with metabolic syndrome) found that a 10% reduction in subcutaneous adipose volume correlated with a statistically significant 12% increase in dermal collagen density by reflectance confocal microscopy [8]. If AOD-9604 produces meaningful subcutaneous fat reduction, improved dermal collagen metrics could follow, but the causation runs through fat loss, not through direct peptide-to-fibroblast signaling.

Sebum Production and Acne Risk

This is a common patient concern when starting any GH-adjacent peptide. Full-length GH raises sebum production via IGF-1-driven sebocyte proliferation, which is why acne is a recognized side effect of GH therapy listed in the FDA-approved labeling for Norditropin [9]. AOD-9604 lacks this mechanism. The Heffernan study found no change in sebum-related markers in treated animals [2], and no published human report documents AOD-9604-induced acne as a treatment-emergent adverse event with confirmed causation.

Skin Hydration and Glycosaminoglycan Content

GH and IGF-1 stimulate hyaluronic acid synthesis in dermal fibroblasts, contributing to the "plumper" skin texture some patients associate with peptide use. Because AOD-9604 does not raise IGF-1, no mechanism supports hyaluronic acid-mediated skin hydration changes from this peptide specifically. Any improvement in skin hydration reported by patients is more plausibly attributable to concurrent lifestyle changes, hydration habits, or placebo response.

AOD-9604 vs. Other Peptides Prescribed for Skin and Hair

Clinicians prescribing peptides for aesthetic endpoints typically compare AOD-9604 against GHRPs (like ipamorelin or CJC-1295 without DAC), BPC-157, and GHK-Cu.

GHRP Comparisons

Ipamorelin at 200 to 300 mcg three times daily raises GH pulse amplitude and secondarily increases IGF-1, producing the skin-thickness and collagen benefits documented for GH itself. A 2003 study in Growth Hormone and IGF Research showed that ipamorelin produced a 39% increase in GH AUC in healthy men aged 18-45 over 15 days at 200 mcg three times daily [10]. AOD-9604 does not produce comparable IGF-1 elevation and cannot be expected to deliver equivalent skin outcomes.

GHK-Cu and Direct Follicular Effects

GHK-Cu (copper tripeptide) has demonstrated direct stimulatory effects on hair follicle keratinocytes in vitro, with one controlled trial (N = 40, 6 months topical GHK-Cu vs. Minoxidil 2%) published in Archives of Dermatological Research showing equivalent hair density outcomes at 6 months between arms [11]. AOD-9604 has no published topical application data and no established mechanism for direct follicular keratinocyte stimulation.

BPC-157 and Skin Healing

BPC-157 has shown accelerated wound healing in rodent models via VEGF upregulation, with a study in the Journal of Physiology (Zagreb) demonstrating 40% faster full-thickness wound closure in rats receiving 10 mcg/kg/day intraperitoneally versus saline controls [12]. AOD-9604 does not share this VEGF-mediated wound-healing pathway.

Safety Profile Relevant to Hair and Skin

AOD-9604 received GRAS (Generally Recognized as Safe) status from the FDA for use as a food ingredient at low doses following a safety review that examined 12 weeks of oral administration in healthy volunteers [13]. The compound reached Phase II human trials under Metabolic Pharmaceuticals (METAOD001, METAOD003) without serious adverse events reported in the trial summaries, and no dermatological adverse events were listed as dose-limiting in the publicly available summary data.

The peptide does not appear to suppress the hypothalamic-pituitary-gonadal axis. A review of peptide safety profiles published in Endocrine Reviews (2022) noted that C-terminal GH fragments including 176-191 do not bind androgen receptors or SHBG, making androgenic alopecia acceleration an unlikely mechanism for any hair loss observed during treatment [14].

Injection-Site Reactions

Subcutaneous injections of any peptide carry a risk of localized lipoatrophy, especially with repeated injection at the same site. Lipoatrophy in the scalp or facial subcutaneous layer (if injected in those areas off-label for local fat reduction) could produce surface contour changes that patients might describe as skin texture irregularities. Rotating injection sites reduces this risk substantially.

Drug Interactions Affecting Hair and Skin

No pharmacokinetic drug-interaction studies for AOD-9604 have been published in peer-reviewed literature as of July 2025. Patients concurrently using finasteride or minoxidil for androgenic alopecia should understand that any hair changes they observe cannot be cleanly attributed to AOD-9604 versus their established hair-loss therapy.

Current Evidence Gaps and What Clinicians Need

The single most important gap in the literature is the absence of a placebo-controlled human trial measuring AOD-9604's effect on any dermatological endpoint. The Endocrine Society's clinical practice guideline on GH and GH-related peptides (2019 update) explicitly states that "off-label peptide fragments of GH require prospective controlled trials before dermatological or trichological claims can be supported" [15]. That standard has not been met for AOD-9604.

Three evidence gaps stand out:

1. No published trichoscopy or phototrichogram data from AOD-9604-treated human subjects
2. No dermal collagen density measurements (via ultrasound or reflectance confocal microscopy) from controlled AOD-9604 trials
3. No dose-finding study for any skin or hair endpoint in the 503A prescribing context

Until these data exist, any clinical recommendation about AOD-9604 for hair or skin should be framed as off-label and investigational, with informed consent documenting the absence of controlled human evidence for these specific outcomes.